摘要 In recent years, there has been considerable controversy concerning the discovery and translation into clinical practice of the prostate-specific antigen (PSA) [1-4].In this brief review, I offer the relevant historical facts as I believe them to be true.
Abstract: In recent years, there has been considerable controversy concerning the discovery and translation into clinical practice of the prostate-specific antigen (PSA) [1-4].In this brief review, I offer the relevant historical facts as I believe them to be true.
William J. Catalona. History of the discovery and clinical translation of prostate-specific antigen[J]. Asian Journal of Urology, 2014, 1(1): 12-14.
William J. Catalona. History of the discovery and clinical translation of prostate-specific antigen. Asian Journal of Urology, 2014, 1(1): 12-14.
Catalona WJ. The ‘True' History of the Discovery of ProstatespecificAntigen. The ASCO Post, December 15, 2012, Volume 3,Issue 18. http://www.ascopost.com/issues/december-15-2012/the-%E2%80%98true%E2%80%99-history-of-the-discovery-ofprostate-specific-antigen.aspx (accessed 6-2-14).
[2]
Chu TM. Prostate Specific Antigen (PSA):The Historical Perspectivehttp://www.medicine.mcgill.ca/mjm/v02n02/psa.html (accessed6-2-14)
[3]
Rao AR, Motiwala HG, Karim OMA. The discovery of prostatespecificantigen. BJU Int 2008; 101: 5-10.
[4]
De Angelis D, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L,Semjonow A. Twenty years of PSA: from prostate antigen to tumormarker. Rev Urol 2007; 9: 113-123.
[5]
Gutman AB, Gutman EB. An “acid” phosphatase occurring in theserum of patients with metastasizing carcinoma of prostate gland. JClin Invest 1938; 17: 473-8.
[6]
Flocks RH, Urich VC, Patel CA, OPITZ JM. Studies on theantigenic properties of prostatic tissue. I. J Urol 1960; 84: 134-43.
Hara M, Inoue T, Koyanagi Y, et al. Preparation an dimmunoelectrophoretic assessment of antisera to human seminalplasma. Nippon Hoigaku Zasshi 1966; 20: 356.
[9]
Li TS, Behrman SJ. The sperm- and seminal plasma-specificantigens of human semen. Fertil Steril 1970; 21: 565-73.
[10]
Li TS, Beling CG. Isolation and characterization of two specificantigens of human seminal plasma. Fertil Steril 1973; 24: 134-44.
[11]
Ablin RJ, Soanes WA, Bronson P, Witebsky E. Precipitating antigensof the normal human prostate. Reprod Fertil 1970; 22: 573-4.
[12]
Ablin RJ, Bronson P, Soanes WA, Witebsky E. Tissue- and speciesspecificantigens of normal human prostatic tissue. J Immunol 1970;104: 1329-39.
[13]
Ablin RJ. Immunologic studies of normal, benign, and malignanthuman prostatic tissue. Cancer 1972; 29: 1570-4.
[14]
Sensabaugh GF. Isolation and characterization of a semen-specificprotein from human seminal plasma: a potential new marker forsemen identification. J Forensic Sci 1978; 23: 106-15.
[15]
Sensabaugh GF, Blake ET. Seminal plasma protein p30. Simplifiedpurification and evidence for identity with prostate specific antigen.J Urol 1990; 144: 1523-6.
[16]
Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of ahuman prostate specific antigen. Invest Urol 1979; 17: 159-63.
[17]
Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM.A prostate antigen in sera of prostatic cancer patients. Cancer Res1980; 40: 2428-32.
[18]
Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T,Valenzuela L, et al. Quantitation of prostate-specific antigen inserum by a sensitive enzyme immunoassay. Cancer Res 1980; 40:4658-62.
[19]
US patent number 4446122. Available at http://patft.uspto.gov/netahtml/PTO/ search-bool.html Accessed May 2007
[20]
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E.Prostate-specific antigen as a serum marker for adenocarcinoma ofthe prostate. N Engl J Med 1987; 317: 909-16.
[21]
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, YuanJJ, et al. Measurement of prostate-specific antigen in serum as ascreening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.
[22]
Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT,Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostatecancer: results of a multicenter clinical trial of 6,630 men. J Urol1994; 151: 1283-90.
[23]
Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, etal. Longitudinal evaluation of prostate-specific antigen levels in menwith and without prostate disease. JAMA1992; 267: 2215-20.
[24]
Veneziano S, Pavlica P, Querzé R, Nanni G, Lalanne MG, Vecchi F.Correlation between prostate-specific antigen and prostate volume,evaluated by transrectal ultrasonography: usefulness in diagnosis ofprostate cancer. Eur Urol 1990; 18: 112-6.
[25]
Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA,et al. Prostate specific antigen density: a means of distinguishingbenign prostatic hypertrophy and prostate cancer. J Urol 1992; 147:815-6.
[26]
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC,Patel A, et al. Use of the percentage of free prostate-specific antigento enhance differentiation of prostate cancer from benign prostaticdisease: a prospective multicenter clinical trial. JAMA 1998; 279:1542-7.
[27]
Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, BangmaCH, et al. A multicenter study of [-2]pro-prostate specific antigencombined with prostate specific antigen and free prostate specificantigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostatespecific antigen range. J Urol 2011; 185: 1650-5.
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, etal. Quantifying the role of PSA screening in the US prostate cancermortality decline. Cancer Causes Control 2008; 19: 175-81.
[30]
Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, HeijnsdijkEA, et al. The prostate cancer conundrum revisited: treatmentchanges and prostate cancer mortality declines. Cancer 2012; 118:5955-63.
[31]
Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH,Schmidlin F, et al. Recent trends in prostate cancer mortality showa continuous decrease in several countries. Int J Cancer 2008; 123:421-9.
[32]
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, NelenV, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl JMed 2012; 366: 981-90.
[33]
Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P,et al. Mortality results from the Göteborg randomized populationbasedprostate-cancer screening trial. Lancet Oncol 2010; 11:725-32.
[34]
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, GreeneKL, et al. Early detection of prostate cancer: AUA Guideline. J Urol2013; 190: 419-26.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
